Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

ployee stock-based compensation are excluded because of varying available valuation methodologies, subjective assumptions and the variety of award types; such exclusion facilitates comparisons of Onyx's operating results to peer companies.Imputed interest related to the convertible senior notes due 2016: The effects of imputed interest related to the convertible senior notes due 2016 are excluded because this expense is non-cash; such exclusion facilitates comparisons of Onyx's cash operating results to peer companies.Advance funding to S*BIO and impairment of equity investment in S*BIO: The effects of the termination of the S*BIO collaboration agreement are excluded because they do not relate to the normal and recurring transactions of Onyx's business; such exclusion allows for a better representation of the ongoing economics of the business, facilitates comparison to peer companies and is reflective of how Onyx management internally manages the business.Lease termination exit costs: The effects of lease termination exit costs are excluded because they represent non-cash items that relate to Onyx's exit from facilities it previously occupied in Emeryville and in South San Francisco, California.(6) Under the "if-converted" method, interest and issuance costs and potential common shares related to the Company's convertible senior notes were excluded from non-GAAP diluted per share amounts for the three and nine months ended September 30, 2011 and 2010 because their effect would be anti-dilutive.ONYX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)September 30,December 31,20112010(7)(unaudited)AssetsCash, cash equivalents and current marketable securities

$
506,887$
549,313Other current assets

70,16795,871Total current assets

577,054645,184Marketable securities, non-current

22,84128,555Property and equipment, net

19,65010,822Intangible assets - in-process research and development


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... - Phase 2 trial expected to begin in late ... June 4 Nuvelo, Inc.,(Nasdaq: NUVO ) today ... a,single-center, Phase 1b trial to determine the safety, tolerability ... direct,thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers., ...
... at American Society of Clinical Oncology meeting indicate ... compared to historical data., PRINCETON, N.J., June ... CPX-1 Phase 2 clinical trial in patients,with advanced ... and floxuridine, based on the company,s proprietary,CombiPlex(TM) technology. ...
Cached Medicine Technology:Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 2Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 3Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has ... , The acquisition includes all of IBAM NA’s cyclotron sites and research and development ... robust regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Programs, with accountability for overall performance of the company’s Medicare and Federal Employee ... of Cambia’s strategy to deliver better health for members. In this role, Scott ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... provider of medical information, risk management and investigative services, has introduced a ... toward focused, expert information solutions that improve business outcomes for its customers. ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Did you ... or Orange County looking for exceptional and affordable home care options which A-1 Home ... are just a few of the credentials A-1 Home Care Agency is ...
Breaking Medicine News(10 mins):Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3
... Niche, Healthcare-Career Site Recognized by Candidate Community , ... ... onTargetjobs Inc. (OTJ) company and North America,s premier healthcare ... named as this year,s top job sites., , , , ,"With ...
... 3 Though one in three women in this country ... receiving the same in-hospital treatment that men do for heart ... die. (Please copy and paste the following link into your ... a big concern. For example, women are 14% less likely ...
... Feb. 3 ETHEX Corporation, a subsidiary of KV ... nationwide recall of the products identified below (all lots ... The Company is taking this action as a precautionary ... conditions that did not sufficiently comply with current Good ...
... Feb. 3 Brent McKenzie, based in ... the nation,s fastest growing,pharmacy benefit firm, as ... Mr. McKenzie offers his clients over 25 ... and Pharmacy Benefit Management arena.,Brent has worked ...
... products containing nanomaterials must immediately institute high-quality risk ... liability exposure in the future, assert attorneys Jesse ... be thoroughly explored at FDLI,s 2nd Annual Conference ... 2009, in Washington, D.C., and discussed in a ...
... 2009) Green tea products have become regarded as ... of its benefit against a variety of diseases, including ... green tea may counteract the anticancer effects of one ... be contraindicated for patients taking this medicine to ensure its ...
Cached Medicine News:Health News:HEALTHeCAREERS Network Receives WEDDLE's 2009 User's Choice Award 2Health News:ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level 2Health News:ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level 3Health News:Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting 2Health News:Risk-Management Policies Needed Now in Nanotechnology, Insighter Piece Concludes; FDLI Sponsors Nanotechnology Meeting, Publishes Book on FDA-Regulated Products 2Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3
... The IEC CL40 and FL40 Centrifuge ... safety and versatility to increase your ... a broad array of rotors and ... and microplate applications, the IEC CL40 ...
... IEC CL40 and FL40 Centrifuge Series ... and versatility to increase your productivity ... broad array of rotors and accessories ... microplate applications, the IEC CL40 and ...
... Glucose Monitoring System has the largest reading ... easy to see and hold. FreeStyle Freedom ... smallest sample of blood. And it's fastyou'll ... seconds. With 4 programmable alarms, you'll know ...
Platelet Aggregation Profiler...
Medicine Products: